Literature DB >> 18711182

Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma.

Karen E Hoffman1, Ming-Hui Chen, Rinaa S Punglia, Clair J Beard, Anthony V D'Amico.   

Abstract

PURPOSE: Adjuvant radiation therapy (ART) for stage I seminoma can cause adverse late effects and alternative postorchiectomy management strategies have been developed. This study evaluated ART trends in the United States and the impact of clinical and sociodemographic factors on ART recommendations.
METHODS: Of men diagnosed with stage I seminoma from 1990 through 2004, 3,125 were identified using the Surveillance, Epidemiology, and End Results cancer registry. A multivariable logistic regression analysis was performed to assess whether there was a significant association between diagnosis year, diagnosis age, race, county education level, region, tumor size, tumor category, and the recommendation for ART.
RESULTS: There was a significant association (P < .001) between later year of diagnosis and a decrease in ART recommendation. Compared with men diagnosed in 1990 to 1994, men diagnosed in 1995 to 1999, and 2000 to 2004 were less likely to have ART (adjusted odds ratio [OR], 0.63; 95% CI, 0.48 to 0.84; and OR, 0.49; 95% CI, 0.37 to 0.63, respectively). There also was a significant association (P < .001) between county education level and ART recommendation. Men residing in counties with the highest education level were more likely to receive ART than men residing in counties with the lowest education level (OR, 2.12; 95% CI, 1.59 to 2.82). Also, men older than 30 years were more likely to receive ART than men age 30 or younger (OR, 1.26; 95% CI, 1.03 to 1.55).
CONCLUSION: ART recommendations for stage I seminoma are declining. Men in less educated regions and the youngest men were less likely to receive a recommendation for ART.

Entities:  

Mesh:

Year:  2008        PMID: 18711182      PMCID: PMC2867767          DOI: 10.1200/JCO.2008.16.5043

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  37 in total

1.  The prevalence of limited health literacy.

Authors:  Michael K Paasche-Orlow; Ruth M Parker; Julie A Gazmararian; Lynn T Nielsen-Bohlman; Rima R Rudd
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

2.  Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes?

Authors:  S Bieri; M Rouzaud; R Miralbell
Journal:  Radiother Oncol       Date:  1999-03       Impact factor: 6.280

3.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.

Authors:  Lois B Travis; Sophie D Fosså; Sara J Schonfeld; Mary L McMaster; Charles F Lynch; Hans Storm; Per Hall; Eric Holowaty; Aage Andersen; Eero Pukkala; Michael Andersson; Magnus Kaijser; Mary Gospodarowicz; Timo Joensuu; Randi J Cohen; John D Boice; Graça M Dores; Ethel S Gilbert
Journal:  J Natl Cancer Inst       Date:  2005-09-21       Impact factor: 13.506

Review 4.  Variations in breast cancer treatment by patient and provider characteristics.

Authors:  J Z Ayanian; E Guadagnoli
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma.

Authors:  J M Bachaud; F Berthier; M Soulié; B Malavaud; P Plante; P Rischmann; C Chevreau; N Daly-Schveitzer; P Grosclaude
Journal:  Radiother Oncol       Date:  1999-02       Impact factor: 6.280

6.  Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma.

Authors:  Richard Choo; Gillian Thomas; Tony Woo; David Lee; Brian Kong; Neil Iscoe; Cyril Danjoux; Laurie Klotz; Gerard Morton; Sarat Chander
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

7.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Authors:  R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

8.  Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002.

Authors:  Scott Tyldesley; David Voduc; Michael McKenzie; Graeme Duncan; Mitchell Liu; Douglas Wu
Journal:  Urology       Date:  2006-03       Impact factor: 2.649

9.  Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute.

Authors:  C Zippin; D Lum; B F Hankey
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

Review 10.  Origins of socio-economic inequalities in cancer survival: a review.

Authors:  L M Woods; B Rachet; M P Coleman
Journal:  Ann Oncol       Date:  2005-09-02       Impact factor: 32.976

View more
  14 in total

1.  Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study.

Authors:  Michael T Milano; Huilin Li; Mitchell H Gail; Louis S Constine; Lois B Travis
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

Review 2.  Testicular cancer: a narrative review of the role of socioeconomic position from risk to survivorship.

Authors:  Lisa C Richardson; Antonio J Neri; Eric Tai; Jeffrey D Glenn
Journal:  Urol Oncol       Date:  2011-11-27       Impact factor: 3.498

3.  Increased mortality among Hispanic testis cancer patients independent of neighborhood socioeconomic status: a SEER study.

Authors:  Timothy V Johnson; Wayland Hsiao; Ashesh Jani; Viraj A Master
Journal:  J Immigr Minor Health       Date:  2011-10

4.  The Evolving Management of Patients With Clinical Stage I Seminoma.

Authors:  Richard S Matulewicz; Daniel T Oberlin; Joel Sheinfeld; Joshua J Meeks
Journal:  Urology       Date:  2016-08-12       Impact factor: 2.649

Review 5.  Clinical stage I seminoma: the case for surveillance.

Authors:  Nathan Lawrentschuk; Neil Fleshner
Journal:  World J Urol       Date:  2009-06-11       Impact factor: 4.226

6.  Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors.

Authors:  Pei Dong; Zhuo-Wei Liu; Xiang-Dong Li; Yong-Hong Li; Kai Yao; Song Wu; Zi-Ke Qin; Hui Han; Fang-Jian Zhou
Journal:  Med Oncol       Date:  2013-02-12       Impact factor: 3.064

7.  Stage I testicular seminoma: a SEER analysis of contemporary adjuvant radiotherapy trends.

Authors:  Alan E Thong; Daphne Y Lichtensztajn; Leanne Almario; Alexandre Ingels; Scarlett Lin Gomez; Mark L Gonzalgo
Journal:  J Urol       Date:  2013-04-06       Impact factor: 7.450

8.  Outcomes in stage I testicular seminoma: a population-based study of 9193 patients.

Authors:  Clair J Beard; Lois B Travis; Ming-Hui Chen; Nils D Arvold; Paul L Nguyen; Neil E Martin; Deborah A Kuban; Andrea K Ng; Karen E Hoffman
Journal:  Cancer       Date:  2013-04-30       Impact factor: 6.860

Review 9.  Pure seminoma: a review and update.

Authors:  Noureddine Boujelbene; Adrien Cosinschi; Nadia Boujelbene; Kaouthar Khanfir; Shushila Bhagwati; Eveleyn Herrmann; Rene-Olivier Mirimanoff; Mahmut Ozsahin; Abderrahim Zouhair
Journal:  Radiat Oncol       Date:  2011-08-08       Impact factor: 3.481

10.  Increased stomach cancer risk following radiotherapy for testicular cancer.

Authors:  M Hauptmann; S D Fossa; M Stovall; F E van Leeuwen; T B Johannesen; P Rajaraman; E S Gilbert; S A Smith; R E Weathers; B M P Aleman; M Andersson; R E Curtis; G M Dores; J F Fraumeni; P Hall; E J Holowaty; H Joensuu; M Kaijser; R A Kleinerman; F Langmark; C F Lynch; E Pukkala; H H Storm; L Vaalavirta; A W van den Belt-Dusebout; L B Travis; L M Morton
Journal:  Br J Cancer       Date:  2014-11-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.